A new drug combination shrank tumors or stopped cancer growth in nine out of ten patients with advanced pancreatic cancer, according to clinical trial results presented at an international cancer conference in Barcelona. The experimental treatment doubled the typical time before disease progression and could offer hope for one of the deadliest cancer types.
Trial Results Show Significant Tumor Response
The phase 1/2 trial tested an experimental daily pill called daraxonrasib alongside two standard chemotherapy drugs, gemcitabine and nab-paclitaxel. Researchers tracked 61 patients whose pancreatic cancer had already spread to other organs. Tumors shrank in 60.7 percent of cases, with 8.2 percent showing complete disappearance on scans. The combination stopped tumor growth in 90.2 percent of participants, far exceeding typical chemotherapy results.
Patients went a median of 12.8 months before their cancer worsened, nearly double the five to six months typically seen with standard chemotherapy alone. At the one-year mark, 76.6 percent of participants remained alive. Standard chemotherapy alone typically shrinks tumors in only 23 to 42 percent of patients with metastatic pancreatic cancer, with most surviving between 8 and 11 months.
bbc.com/news/articles/…
Targeting a Previously Untreatable Mutation
The drug addresses a faulty gene called RAS, which drives more than 90 percent of pancreatic cancers and allows tumors to continue growing. Scientists long considered this genetic defect impossible to treat with medication. Daraxonrasib works by turning off the growth signal that RAS produces, representing a breakthrough in cancer treatment approaches.
Dr. Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center in New York who led the study, noted the treatment produced not only substantial tumor shrinkage, including complete responses, but also durable disease control. Side effects included rash, diarrhea, fatigue and low blood cell counts, though most proved manageable with standard care. Only 5 percent of patients stopped treatment due to side effects from daraxonrasib.
What This Means for Patients
Pancreatic cancer remains notoriously difficult to treat because more than half of patients receive diagnoses after the disease has already spread. National Cancer Institute data shows only about 3 percent of patients with distant-stage disease survive five years past diagnosis. Researchers cautioned that this early-phase study lacked a direct comparison group receiving standard chemotherapy alone, making it impossible to definitively confirm survival benefits yet. Revolution Medicines, the California-based company developing daraxonrasib, funded the trial and has launched a larger phase 3 trial called RASolute-303 to verify whether these results translate into longer survival.

